RCW 70.405.010 Definitions. The definitions in this section apply throughout this chapter unless the context clearly requires otherwise. (1) “Authority” means the health care authority. (2) “Biological product” has the same meaning as in 42 U.S.C. Sec. 262(i)(1). (3) “Biosimilar” has the same meaning as in 42 U.S.C. Sec. 262(i)(2). (4) “Board” means the prescription […]
RCW 70.405.020 Prescription drug affordability board. (1) The prescription drug affordability board is established, to include five members who have expertise in health care economics or clinical medicine appointed by the governor. (2) Board members shall serve for a term of five years and members may be reappointed by the governor for additional terms. (3) […]
RCW 70.405.030 Authority to review drug prices. By June 30, 2023, and annually thereafter, utilizing data collected pursuant to chapter 43.71C RCW, the all-payer health care claims database, or other data deemed relevant by the board, the board must identify prescription drugs that have been on the market for at least seven years, are dispensed […]
RCW 70.405.040 Affordability reviews. (1) The board may choose to conduct an affordability review of up to 24 prescription drugs per year identified pursuant to RCW 70.405.030. When deciding whether to conduct a review, the board shall consider: (a) The class of the prescription drug and whether any therapeutically equivalent prescription drugs are available for […]
RCW 70.405.050 Upper payment limits. (1) The authority must adopt rules setting forth a methodology established by the board for setting upper payment limits for prescription drugs the board has determined have led or will lead to excess costs based on its affordability review. The rules adopted under this subsection may not go into effect […]
RCW 70.405.060 Use of savings. (1) Any savings generated for a health plan, as defined in RCW 48.43.005, or a health plan offered under chapter 41.05 RCW that are attributable to the establishment of an upper payment limit established by the board must be used to reduce costs to consumers, prioritizing the reduction of out-of-pocket […]
RCW 70.405.070 Manufacturer withdrawal from the market. (1) Any manufacturer that intends to withdraw a prescription drug from sale or distribution within the state because the board has established an upper payment limit for that drug shall provide a notice of withdrawal in writing indicating the drug will be withdrawn because of the establishment of […]
RCW 70.405.080 Reporting. By December 15, 2022, and annually thereafter, the board shall provide a comprehensive report to the legislature detailing all actions the board has taken in the past year, including any rules adopted by the authority pursuant to chapter 153, Laws of 2022, establishing any processes, such as the methodology for the upper […]
RCW 70.405.090 Rule making. The authority may adopt any rules necessary to implement this chapter. The rules adopted under this section may not go into effect until at least 90 days after the next regular legislative session. [ 2022 c 153 § 9.]
